tbuckley/cabot-search huggingface dataset:
Abstract 5568: Thermochemotherapy with controlled drug delivery using a novel magnetic anti-cancer drug .
Authors: Itaru Sato, Kenji Mitsudo, Masanari Umemura, Xianfeng Feng, Hidenobu Fukumura, Haruki Eguchi, Hideyuki Nakashima, Mitomu Kioi, Iwai Tohnai, Yoshihiro Ishikawa
Journal: Cancer Research (2013)

Abstract Background: Radical surgery for patients with oral cancer may cause dysfunction, such as dysphagia, dysarthria, or mastication disorders, leading to decreased quality of life in cancer patients. Here, we report the development of a novel magnetic anti-cancer drug, EI236, which may enable us to reduce such problems. EI236 possesses three features; anti-cancer effect alike cisplatin, controlled drug delivery using a magnet, and hyperthermic effect upon exposure to an alternating current magnetic field (ACMF). We thus examined the efficacy of EI236 in treating oral cancer in a rabbit cancer model. Methods: Cell proliferation was measured by MTT assays. We established the rabbit tongue cancer model using VX2 cells, which are readily transplantable in vivo. Electromagnet was used to attract EI236 to the site of tongue cancer by controlled drug delivery (CDR), and ACMF to generate heat from EI236 (HT). Rabbits were divided into 4 groups: control group, intravenous EI236 injection group (5mg/kg×7days) (i.v.), intravenous EI236 injection + electromagnet group (i.v. + CDR), intravenous EI236 injection + electromagnet + ACMF group (i.v. + CDR + HT). The size of tumors was measured daily for 7 days, followed by histopathological evaluation. Of note, EI236 was injected at the same dose in the three groups. Results: EI236 showed anti-cancer effects in a dose-dependent manner in VX2 cells. The IC50 value of EI236 was 7.5μM in cultured cells. The resultant tumor volume after EI236 i.v. injection treatment in rabbits was as follows; 319.3±40.0% for control, 228.5±94.3% for i.v., 91.5±27.4X% for i.v. + CDR, 24±8.2% for i.v. + CDR + HT, indicating that the i.v. + CDR + HT group showed the greatest decrease. It also showed the largest necrotic area in H-E staining analysis. The tumor cell nucleus, as determined by Ki67 staining, were mostly disappeared. Conclusion: Anti-cancer effect of EI236 was synergistically increased in the presence of CDR and/or HT. EI236 may serve as a novel anti-cancer therapy that enables CDR and HT at the same time. Citation Format: Itaru Sato, Kenji Mitsudo, Masanari Umemura, Xianfeng Feng, Hidenobu Fukumura, Haruki Eguchi, Hideyuki Nakashima, Mitomu Kioi, Iwai Tohnai, Yoshihiro Ishikawa. Thermochemotherapy with controlled drug delivery using a novel magnetic anti-cancer drug . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5568. doi:10.1158/1538-7445.AM2013-5568
Gamma Probe–Guided Resection and Scanning with Tc-99m MIBI of a Local Recurrence of Follicular Thyroid Carcinoma
Authors: A Boz, C Arici, F Güngör, A Yildiz, T Colak, B Karayalçin
Journal: Clinical Nuclear Medicine (2001)

A 30-year-old woman underwent two operations for multinodular goiter and follicular thyroid carcinoma. The residual thyroid tissue was ablated by I-131 therapy. After 7 years of follow-up, Tc-99m MIBI and I-131 scintigraphy were performed, because her serum thyroglobulin level was much higher compared with the control analysis performed in the sixth year. Tc-99m MIBI showed pathologic accumulation, which could be consistent with a local recurrence, whereas the results of I-131 scintigraphy were negative. The locally recurring follicular thyroid carcinoma was resected using a gamma probe and Tc-99m MIBI. The thyroglobulin level decreased to a normal level after surgery. This case shows that the intraoperative use of a gamma probe with Tc-99m MIBI allows localization of recurrent thyroid tissue in the scarred area in patients with increased radionuclide accumulation, and scanning of the affected area using the gamma probe may be helpful in determining whether resection is complete.
White House Physician Lee to be Active In Health Policy
Authors: L. F. Anderson
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article White House Physician Lee to be Active In Health Policy Get access Linda F. Anderson Linda F. Anderson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 9, 3 May 1989, Pages 659–660, https://doi.org/10.1093/jnci/81.9.659 Published: 03 May 1989
AB0544 Efficacy and safety of tocilizumab in patients with rheumatoid arthritis in the presence or absence of previous treatment with biologics and concomitant treatment with methotrexate:
Authors: K. Izumi, Y. Kaneko, H. Yasuoka, N. Seta, H. Kameda, M. Kuwana, T. Takeuchi
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To determine whether efficacy and safety of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) are different or not in the presence or absence of previous treatment with biologics and concomitant treatment with methotrexate (MTX). <h3>Methods</h3> We examined clinical background of RA patients who started TCZ in Keio University Hospital between July 2008 and May 2011, and prospectively evaluated their clinical and functional status and safety, stratified according to previous use of biologics (pre-Bio) and concomitant use of MTX (con-MTX). <h3>Results</h3> A total of 101 patients (12 males, 89 females) were classified as follows: 28 patients in <i>Group A</i> (<i>pre-Bio and con-MTX),</i> 20 patients in <i>Group B</i> (<i>pre-Bio without con-MTX)</i>, 26 patients in <i>Group C</i> (<i>con-MTX without pre-Bio)</i>, and 27 patients in <i>Group D</i> (<i>neither pre-Bio nor con-MTX)</i>. Overall age (mean±SD) at the commencement of TCZ was 56.2±13.2 years, average DAS28-ESR 5.03±1.36, average HAQ-DI 1.11±0.74, duration of TCZ administration 49.3±35.2 weeks, and the proportion of patients treated with concomitant prednisolone 46%. No significant differences were noted among the 4 groups in terms of demographic and clinical features, except for duration of disease (Table). The proportions of patients achieving DAS28-ESR &lt;2.6 at week 24 in Group A, B, C and D were 57.9%, 60.0%, 66.7% and 60.0%, respectively, which were comparable among the groups. The retention rate of TCZ at week 24 was 86.4% in Group A, 77.0% in Group B, 95.0% in Group C, and 100% in Group D. By week 24, 7 patients discontinued TCZ: 2 lack of efficacy (LOE) and 1 adverse event (AE) of eruption in Group A, 1 LOE and 2 AEs (nausea, small-intestinal perforation) in Group B, and 1 LOE in Group C. <h3>Conclusions</h3> The efficacy of TCZ was observed in RA patients regardless of prior or concomitant treatment for RA, while discontinuation of TCZ due to AE tended to be observed in those with prior biological therapies. <h3>Disclosure of Interest</h3> None Declared
AB0931 Validity and reliability of the dutch version of the psoriatic arthritis quality of life (PSAQOL) questionnaire
Authors: F. Wink, S. Arends, S.P. McKenna, E. van der Veer, P.M. Houtman, E. Brouwer, A. Spoorenberg
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Generic health status instruments such as the Health Assessment Questionnaire (HAQ), the Arthritis Impact Measurement Scale (AIMS) and the 36-item Short Form Health Survey (SF-36) are commonly used to attempt to evaluate the total impact of psoriatic arthritis (PsA). However, these questionnaires predominantly focus on impairment and disability rather than quality of life (QoL). McKenna et al. have developed and validated the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire. This is a disease specific instrument developed to measure QoL in patients with PsA (1). <h3>Objectives</h3> To assess the construct validity and test-retest reliability of the Dutch version of the PsAQoL. <h3>Methods</h3> In total 209 consecutive outpatients were available for a test-retest postal survey to investigate the construct validity and test-retest reliability of the Dutch version of the PsAQoL. All patients fulfilled the Classification criteria of Psoriatic Arthritis (CASPAR) for PsA. The PsAQoL, Health Assessment Questionnaire (HAQ) and Skindex-17 were administered on two different occasions approximately two weeks apart. Construct validity was examined by calculating Spearman’s correlation coefficients between the PsAQoL score and the HAQ and Skindex-17 scores. Test-retest reliability was investigated by calculating the intraclass correlation coefficient (ICC) between the first and second assessments of the PsAQoL. Additionally, Bland-Altman analysis was performed <h3>Results</h3> Mean age of the 183 (87.6%) responding PsA patients was 55.4 years (SD± 12.5), median disease duration was 5.5 years (range 0.3-45) and 55% were male. The Dutch version of the PsAQoL showed good association to the HAQ (ρ=0.722) and moderate association to the Skindex-17 (ρ=0.464), indicating acceptable construct validity. Furthermore, good internal consistency (Cronbach’s α=0.920) and test-retest reliability (ICC=0.889) of the PsAQoL were found. Bland-Altman analysis showed no systemic bias between the first and second assessments of the PsAQoL. The limits of agreement (LOA) of the PsAQoL were found between -5.3 and 5.1 out of a total of 20, indicating good agreement. <h3>Conclusions</h3> The Dutch version of the PsAQoL is a valid and reliable questionnaire to use in clinical or research settings to asses disease-related QoL in patients with PsA. <h3>References</h3> McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63:162-9. <h3>Disclosure of Interest</h3> None Declared
AB0796 Disease Modifying Anti Rheumatic Drugs Improve Cardiovascular Autonomic Neuropathy in Psoriatic Arthritis
Authors: A. Syngle, I. Verma, P. Krishan
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Cardiovascular autonomic neuropathy (CAN) is the commonest risk predictor for sudden cardiac death in autoimmune rheumatic diseases.<sup>1-2</sup> As yet, there is no therapeutic treatment of cardiovascular autonomic neuropathy in psoriatic arthritis (PsA). Even, the impact of most commonly employed disease modifying antirheumatic drugs (DMARDs) therapy on cardiovascular autonomic neuropathy in PsA is not known. <h3>Objectives</h3> To investigate the efficacy of DMARDs on cardiovascular autonomic neuropathy in PsA. <h3>Methods</h3> In this perspective open label study, twenty DMARD naive PsA patients who fulfilling the CASPAR (Classification Criteria for Psoriatic Arthritis) criteria and 20 age and sex matched healthy controls were recruited. Cardiovascular autonomic neuropathy was diagnosed by applying the five cardiovascular reflex tests according to Ewing. Disease activity was assessed by 28-joint-count disease activity score (DAS28) and disease activity score in psoriatic arthritis (DAPSA). ESR was measured by Westergreen method and CRP level was determined using standard commercial kits. Autonomic measures were double blinded to the physician and patients for the study duration. Therefore, the patients were treated without influence of the autonomic function data. All clinical investigations were performed at baseline and after weeks 12. <h3>Results</h3> Cardiovascular reflex tests were impaired significantly among the PsA patients compared with well matched healthy subjects (p&lt;0.05). Parasympathetic dysfunction was more prominent than sympathetic dysfunction. After 12 weeks treatment, parasympathetic dysfunction (HR response to deep breath and standing) significantly (p&lt;0.05) improved in patients with PsA, while there was no significant improvement in sympathetic function. 55% (11/20) DMARD naive patients had severe autonomic neuropathy score. After treatment, 72.7% (8/11) improvement was seen in severe autonomic neuropathy in DMARD naive PsA patients. Patients with normal cardiovascular autonomic function had no change in their cardiovascular autonomic function after 12 weeks treatment with synthetic DMARDs. <h3>Conclusions</h3> These study results suggest parasympathetic autonomic dysfunction is more prominent than sympathetic dysfunction in PsA. Synthetic DMARDs improved parasympathetic dysfunction in PsA. <h3>References</h3> Milovanovic B et al. Srp Arh Celok Lek. 2010; 138:26-32. Syngle et al. Clin Rheumatol. 2013;32:59-64. <h3>Acknowledgements</h3> We are very grateful to University Grant Commission, New Delhi (Govt. of India) for providing the research fellowship [No. F.10-15/2007 (SA-I)]. <h3>Disclosure of Interest</h3> None declared
Giant stentolith: complication of a forgotten biliary stent
Authors: V. Gupta, A. Chandra, M. Noushif, S. Singh
Journal: Endoscopy (2013)

A 50-years-old woman underwent open cholecystectomy after endoscopic retrograde cholangiography, clearance of the common bile duct (CBD), and plastic stent placement. She had undergone sphincterotomy for cholangitis 4 years previously, but did not report for follow-up as she apparently remained asymptomatic. She now presented with epigastric pain and jaundice, which she had had for 1 month, with no fever. Laboratory tests were normal except raised levels of serum bilirubin (3.8 mg/dL, normal range < 1.2 mg/dL), serum glutamic oxaloacetic transaminase (SGOT) (61 IU/L, normal range < 43 IU/L), serum glutamic pyruvic transaminase (SGPT) (58 IU/L, normal range < 43 IU/L), and serum alkaline phosphatase (388 IU/L, normal range < 306 IU/L). Abdominal ultrasound revealed a large (18 mm × 15 mm) stone along with a stent within the dilated CBD. Endoscopy confirmed the presence of stent. Endoscopic CBD clearance, however, was not attempted in view of the large size of the stone. Open CBD exploration revealed a large cast of stone (~ 8 cm × 2 cm) encasing the intrabiliary part of the stent ([Fig. 1]), which was removed with difficulty. After choledochoscopy to ensure complete CBD clearance, choledochoduodenostomy was carried out with an uneventful postoperative course.
Abstract 4882: Differential BMP4 and GREM1 protein expression in uterine leiomyosarcoma and leiomyoma.
Authors: Natalia Garcia, Faila Catarina Souza, Isabela Werneck Cunha, Fernando Augusto Soares, Gustavo Arantes Rosa Maciel, Edmund Chada Baracat, Katia Candido Carvalho
Journal: Cancer Research (2013)

Abstract Background: Uterine leiomyosarcoma (ULMS) and leiomyoma (ULM) are smooth muscle tumors with distinct clinical behavior. Little is known about the factors that influence these tumors biology. Differential diagnosis among low grade ULMS and the several clinical forms of ULM is a challenge both in laboratory and pathological routine. Thus, the identification of new molecular markers can help in the differential diagnosis between ULM from ULMS and clinical management. Our aim was to evaluate expression of bone morphogenetic protein - 4 (BMP-4) and Gremlin-1 (GREM1) in uterine leiomyosarcoma and leiomyoma (including leiomyoma with atypia) using immunohistochemistry. Method: 57 patients with ULMS and 30 with ULM, among them 10 ULM with atypia (ULMA) were select. The tissues were used in tissue microarray construction. Immunohistochemistry reaction was performed with monoclonal antibody against BMP-4 and GREM-1 and evaluated using semi-quantitative method. Results: BMP-4 was positive in 43% of the ULMS, 5% ULM and 80% ULMA, respectively. GREM-1 was positive in 67% of the ULMS, 20% ULM and 10% ULMA. BMP-4 is a potent growth factor that is involved in many important biological processes. Gremlin-1 can specifically bind to BMP-4 precursor protein inside cells, which prevents the production and secretion of mature BMP-4. This regulation determines BMP-4 biological effects on cells in the local microenvironment. However, the molecular mechanism of GREM-1/BMP-4 interaction remains unexplored. Conclusion: Ours preliminary results showed that expression of BMP-4 and GREM-1 play an important role in uterine smooth tumors, in while atypical leiomyomas presented higher levels of BMP-4 protein expression and lower levels of GREM-1. However, the role of these proteins interactions must be clarified. Citation Format: Natalia Garcia, Faila Catarina Souza, Isabela Werneck Cunha, Fernando Augusto Soares, Gustavo Arantes Rosa Maciel, Edmund Chada Baracat, Katia Candido Carvalho. Differential BMP4 and GREM1 protein expression in uterine leiomyosarcoma and leiomyoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4882. doi:10.1158/1538-7445.AM2013-4882
Abstract 2043: Deregulated Cdc7/Dbf4 expression promotes DNA repair and checkpoint recovery to enhance survival and associates with poor prognosis in OSCC
Authors: An Ning Cheng, Yu-Kang Lo, Shih Sheng Jiang, Alan Yueh-Luen Lee
Journal: Cancer Research (2012)

Abstract Cdc7 (DDK, Dbf4-dependent kinase) is a serine-threonine kinase and required to initiate DNA replication from each origin. Although Cdc7 and Dbf4 has been shown overexpressed in many human cancer cell lines and certain primary tumors, only few cancer tissue samples were analyzed. In this report, in light of the biological, prognostic, and therapeutic implications of Cdc7 in tumorigenesis, we investigated and found that Cdc7 is overexpressed specifically in malignant non-small-cell lung cancer (NSCLC), colorectal cancer and oral squamous cell carcinoma (OSCC) tissues and Cdc7 expression level is an independent prognosis factor for patient survival in OSCC. Cdc7 is required for DNA replication and higher Cdc7 level is linked to the development of tumor cells, however, increased Cdc7 expression levels do not always correlate with the proliferative status of the tumor cells. Therefore, the underlying mechanism of overexpressed Cdc7/Dbf4 in promoting tumorigenesis still needs to be clarified. Our data suggest that up-regulation of Cdc7 has several roles in promoting tumorigenesis. First, overexpression of Cdc7 promotes cell survival through inhibiting DNA damage-induced cell apoptosis and inducing HR DNA repair. Second, during the early stage, it causes checkpoint activation as well as slow-down of S phase progression and promotes HR DNA repair that may through DSB-mediated mechanism. Third, during the late stage, upon removal of DNA lesions and completion of DNA repair in S-phase, Cdc7 attenuates checkpoint signaling and reactivates DNA replication by promoting the loading of replication initiation proteins Cdc45 as well as the activation of Plk1, which will be important for checkpoint recovery and replication restart. In summary, we have shown that a highly significant association between Cdc7 expression and overall survival in OSCC patient, rendering the prognostic importance and clinical practicability of Cdc7 expression in OSCC. Our studies also indicate that increased Cdc7 expression promotes HR repair and attenuates ATM/ATR checkpoint signaling for recovery of damaged replication forks to enhance the survival of DNA damaging agent-treated tumor cells. These studies will open an avenue to the biological, prognostic, and therapeutic applications of Cdc7 kinase in cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2043. doi:1538-7445.AM2012-2043
P625An insight into the function of immunoproteasomes in immunmodulation: induction of the pattern recognition factor Pentraxin 3 in acute cardiac inflammation
Authors: A Voigt, A Possehl, K Klingel, A Rahnefeld
Journal: Cardiovascular Research (2014)

Invasion of inflammatory cells into the injured heart during viral myocarditis needs to be restricted to a level that supports viral elimination and at the same time prevents detrimental processes such as cardiomyocyte dysfunction and cardiac remodeling. The ubiquitin-proteasome-system (UPS) is vital for cells to preserve the intracellular balance of protein synthesis and destruction. By degrading short-lived poly-ubiquitin-tagged proteins it determines the availability of regulatory proteins and controls different signaling events. Increased proteolytic activity of the UPS upon formation of immunoproteasomes (IP) to preserve cellular viability and to counterbalance detrimental outcomes of inflammation during CoxsackievirusB3 (CVB3)-myocarditis. This study investigated down-stream pathways that are affected by IP-dependent protein degradation to protect the heart from inflammatory damage. The soluble pattern recognition factor long pentraxin 3 (PTX3) was found to be up-regulated in CVB3-myocarditis. PTX3 as part of the innate humoral immune response is known to modulate inflammation by facilitating the clearance of apoptotic cells and simultaneously counterbalancing the invasion of leucocytes into inflamed hearts. PTX3-induction critically relied on intact IP-function. The lack of PTX3-induction as observed in cardiac homogenates from CVB3-infected IP-deficient mice coincided with severe inflammatory cardiac damage. Supporting our in vivo results, further in vitro studies confirmed that cardiomyocytes and macrophages contribute to PTX3 secretion as detected by quantitative real-time PCR, immunoblot analysis and ELISA. Primary cardiomyocytes and bone-marrow derived macrophages up-regulate PTX3 in an IP-dependent manner. Specific inhibition of IP activity by small molecular compounds down-regulated PTX3 levels in TNF-α stimulated cardiomyocytes. Further studies aim to unravel the impact of IP function in the timely control of regulatory proteins that are involved in the regulation of PTX3 transcription. Preliminary data point towards impaired IκBα degradation in IP-deficient cardiomyocytes, thereby limiting NFκB-dependent signaling processes and PTX3 expression. In conclusion, this study reports on the role of timely protein processing by the proteasome system to modulate inflammatory injury in a mouse model of viral myocarditis. IP function is critical for PTX3-induction. Given the disease attenuating potential of PTX3 also in acute myocardial ischemia this study has a high impact for cardiac inflammation in general.